DouYu International Holdings Limited Reports Second Quarter 2021 Unaudited Financial Results
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
DouYu International Holdings Limited to Report Second Quarter 2021 Financial Results on August 16, 2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Online fashion retailer Shein appoints Australian marketing agency
July 30, 2021 10:19
Online fashion platform Shein has appointed marketing agency How Communications to its brand account.
The Chinese e-commerce company is worth an estimated US$15 billion, with some, such as Insider, labelling it as a fast fashion brand, that “encourages a cycle of constant buying”.
The project is in partnership with Melbourne fashion PR agency Effie & Co, and includes an ongoing 12 month PR campaign to establish the Shein brand in Australia.
Ted Wang, country head AUNZ at Shein, said: “The How Communications pitch showed extensive Australian market knowledge; this is important as we aim to raise awareness of Shein’s commitment to local fashion in Australia.”
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
Regulatory News:
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the RISE study The Risperidone Subcutaneous Extended-Release Study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for patients with schizophrenia. Trial enrollment was open to patients 13-65 years of age. In the RISE study, patients treated with the investigational subcutaneous risperidone injection either monthly (q1M) (n=183) or once every two months (q2M) (n=179) experienced a statistically significant delay in time to relapse versus placebo (n=181), the study s primary endpoint, with p